%0 Journal Article %A Chris Ka Pun Mok %A Samuel M.S. Cheng %A Chunke Chen %A Karen Yiu %A Tat-On Chan %A Kiu Cheung Lai %A Kwun Cheung Ling %A Yuanxin Sun %A Lun Lai Ho %A Malik Peiris %A David S Hui %T A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac %D 2021 %R 10.1101/2021.11.02.21265843 %J medRxiv %P 2021.11.02.21265843 %X Background Poor immunogenicity and antibody waning were found in vaccinees of CoronaVac. There is lack of randomized controlled trial (RCT) data to compare the immunogenicity and safety of schedules using homologous and heterologous vaccine as a booster dose.Methods We randomly assigned adults who had received 2 doses of CoronaVac with low antibody response to receive an additional booster dose of either BNT162b2 or CoronaVac. The local and systemic adverse reactions were recorded. Levels of SARS-CoV-2 neutralizing and spike binding antibody in plasma were measured.Findings At one month after the third dose of vaccine, BNT162b2 vaccines elicited significantly higher surrogate virus neutralizing test (sVNT), spike receptor binding, spike N terminal domain binding, spike S2 domain binding levels than CoronaVac. More participants from the BNT162b2 group reported injection site pain and swelling as well as fatigue and muscle pain than those who received CoronaVac as the third dose. The mean results of the sVNT against the wild type, beta, gamma and delta variants in the BNT162b2 boosted group was 96.83%, 92.29%, 92.51% and 95.33% respectively which were significantly higher than the CoronaVac boosted group (Wild type: 57.75%; Beta: 38.79 %; Gamma: 32.22%; Delta: 48.87%)Conclusion Our RCT study shows that BNT162b2 booster dose for those people who poorly responded to the previous vaccination of CoronaVac is significantly more immunogenic than a CoronaVac booster. BNT162b2 also elicits higher levels of SARS-CoV-2 specific neutralizing antibodies to different variants of concern. The adverse reactions were only mild and short-lived.Scientific Knowledge on the Subject Poor immunogenicity and antibody waning were found in vaccinees of CoronaVac. There is lack of randomized controlled trial (RCT) data to compare the immunogenicity and safety of schedules using homologous and heterologous vaccine as a booster dose.What This Study Adds to the Field Our RCT study shows that BNT162b2 booster dose for those people who poorly responded to the previous vaccination of CoronaVac is significantly more immunogenic than a CoronaVac booster. The adverse reactions were only mild and short-lived.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04611243Funding StatementThis research was supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR (COVID1903003; COVID190126) (CKPM, MP and DSH), Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government (NRF-2018M3A9H4055203) (CKPM), US National Institutes of Health (contract no. U01-Grant AI151810) (MP), National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (CKPM and MP), RGC theme-based research schemes (T11-712/19-N and T11-705/21-N) (DSH, MP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (Ref no: 2020.229) and all participants provided written consent. This clinical trial has been registered at ClinicalTrials.gov with identifier NCT04611243I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript %U https://www.medrxiv.org/content/medrxiv/early/2021/11/03/2021.11.02.21265843.full.pdf